|
|
Post by peppy on Aug 25, 2016 16:09:54 GMT -5
6,000/7,000 weekly TRx to break even sounds right. Looking at the IMS chart, we had around 20,000 (21,279 TRx per IMS chart) for the first year of launch). Mike C. has mentioned that we had a $7 million first year sales. To get to an annual sales around $120 million, we will need to increase the annual TRx of 20,000 by 17/18 fold (120/7=17.15), and then you divide it by 52 and you will get a 6,000/7,000 weekly TRx. 6,000/7,000 weekly TRx translates into around 30,000 monthly TRx. Mike c. mentions about a 1.5 million insulin TRx monthly. That means we need to get to 2% of the total monthly insulin (basal + bolus) prescriptions to break even. (However, this only considers the US market and Afrezza alone. If Afrezza gains traction, we will have revenues of Afrezza and other TS products in and out US. So if Afrezza gains traction, I would think if we get to 1% of the total monthly insulin (basal + bolus) prescriptions, we will be very close to break even as we will surely have Afrezza sales outside US to come in later. Looking at the situation from that angle, then if we hit 3,000 TRx weekly, we will be well under our way to break even.) 3,000 TRx weekly is completely feasible, if we recall that, Exubera was at around 2,000 TRx weekly before it was pulled off from the market. Thank you Compound. That explains a lot. first target 500 weekly nrx? then 1,000 weekly new rx? little tiny baby steps.
Compound, who designed your website, Just breathe? The MNKD website needs a product tab. *most importantly The website needs to add a picture out Outsulin. It is so cute.
Afrezza, technosphere insulin. Regular human insulin delivered as a monomer taken with your meal. Onset of activity for TI occurred ca. 25-35 minutes earlier than for
Lispro. TI duration of action is about 2 hours shorter than an equivalent dose of Lispro. www.mannkindcorp.com/Collateral/Documents/English-US/Baughman%20poster%20100-LB%20FINAL%20X2.pdf seeing is believing. screencast.com/t/rU8FNwJ8o1E
|
|
|
|
Post by mnholdem on Aug 25, 2016 16:47:36 GMT -5
6,000/7,000 weekly TRx to break even sounds right. Looking at the IMS chart, we had around 20,000 (21,279 TRx per IMS chart) for the first year of launch). Mike C. has mentioned that we had a $7 million first year sales. To get to an annual sales around $120 million (the current annual cash burn of Mannkind), we will need to increase the annual TRx of 20,000 by 17/18 fold (120/7=17.15), and then you divide it by 52 and you will get a 6,000/7,000 weekly TRx. 6,000/7,000 weekly TRx translates into around 30,000 monthly TRx. Mike c. mentions about a 1.5 million insulin TRx monthly. That means we need to get to 2% of the total monthly insulin (basal + bolus) prescriptions to break even. (However, this only considers the US market and Afrezza alone. If Afrezza gains traction, we will have revenues of Afrezza and other TS products in and out US. So if Afrezza gains traction, I would think if we get to 1% of the total monthly insulin (basal + bolus) prescriptions, we will be very close to break even as we will surely have Afrezza sales outside US to come in later. Looking at the situation from that angle, then if we hit 3,000 TRx weekly, we will be well under our way to break even.) 3,000 TRx weekly is completely feasible, if we recall that, Exubera was at around 2,000 TRx weekly before it was pulled off from the market. Sure Pfizer put a lot of sales efforts into marketing Exubera, but Afrezza is much better product. Plus, we now have CGMs, social media and other tail winds for Afrezza. One word: Awareness
There is some very interesting testimony coming out of the shareholder class action lawsuit trial that was dismissed by a federal judge this week. A former Sanofi sales rep testified that Sanofi did not provide either enough reps or enough marketing material for the Sanofi reps to successfully market Afrezza to physicians. With MannKind now driving this bus, events will unfold quite a bit differently. Focus on getting the low-cost spirometry equipment into the hands of the endos, get them up to speed on the proper method for titrating new Afrezza patients, make it easy to deal with insurance carriers and then...
...bring on the marketing.
So few have even heard the name Afrezza, let alone what it can do for patients. Build physician and patient awareness and 3k+ weekly script is feasible indeed.
|
|
|
|
Post by compound26 on Aug 25, 2016 17:03:54 GMT -5
6,000/7,000 weekly TRx to break even sounds right. Looking at the IMS chart, we had around 20,000 (21,279 TRx per IMS chart) for the first year of launch). Mike C. has mentioned that we had a $7 million first year sales. To get to an annual sales around $120 million (the current annual cash burn of Mannkind), we will need to increase the annual TRx of 20,000 by 17/18 fold (120/7=17.15), and then you divide it by 52 and you will get a 6,000/7,000 weekly TRx. 6,000/7,000 weekly TRx translates into around 30,000 monthly TRx. Mike c. mentions about a 1.5 million insulin TRx monthly. That means we need to get to 2% of the total monthly insulin (basal + bolus) prescriptions to break even. (However, this only considers the US market and Afrezza alone. If Afrezza gains traction, we will have revenues of Afrezza and other TS products in and out US. So if Afrezza gains traction, I would think if we get to 1% of the total monthly insulin (basal + bolus) prescriptions, we will be very close to break even as we will surely have Afrezza sales outside US to come in later. Looking at the situation from that angle, then if we hit 3,000 TRx weekly, we will be well under our way to break even.) 3,000 TRx weekly is completely feasible, if we recall that, Exubera was at around 2,000 TRx weekly before it was pulled off from the market. Sure Pfizer put a lot of sales efforts into marketing Exubera, but Afrezza is much better product. Plus, we now have CGMs, social media and other tail winds for Afrezza. One word: Awareness
There is some very interesting testimony coming out of the shareholder class action lawsuit trial that was dismissed by a federal judge this week. A former Sanofi sales rep testified that Sanofi did not provide either enough reps or enough marketing material for the Sanofi reps to successfully market Afrezza to physicians. With MannKind now driving this bus, events will unfold quite a bit differently. Focus on getting the low-cost spirometry equipment into the hands of the endos, get them up to speed on the proper method for titrating new Afrezza patients, make it easy to deal with insurance carriers and then...
...bring on the marketing.
So few have even heard the name Afrezza, let alone what it can do for patients. Build physician and patient awareness and 3k+ weekly script is feasible indeed.
Totally agree. Mike C has stated that despite Sanofi's one year marketing efforts, 90% of the PWDs is not aware of Afrezza. But as Mike said, that's a positive right now. Sanofi reached 627 TRx weekly with "little or no efforts", with 90% of the PWDs not aware of Afrezza. So what happens when 90% of the PWDs is made aware of Afrezza?  |
|
